Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Francois Ringeisen"'
Autor:
Alison Davie, Gebra Cuyun Carter, Alex Rider, James Pike, Katie Lewis, Abigail Bailey, Gregory L. Price, Francois Ringeisen, Xavier Pivot
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. With the introduction of new t
Externí odkaz:
https://doaj.org/article/7fe4847e3d934667a90f1ffc58d8e438
Autor:
Masakazu Toi, Zhimin Shao, Sara Hurvitz, Ling-Ming Tseng, Qingyuan Zhang, Kunwei Shen, Donggeng Liu, Jifeng Feng, Binghe Xu, Xiaojia Wang, Keun Seok Lee, Ting Ying Ng, Antonia Ridolfi, Florence Noel-baron, Francois Ringeisen, Zefei Jiang
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-13 (2017)
Abstract Background The current exploratory analysis was performed to evaluate the efficacy and safety of everolimus for treatment of human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer in the Asian subset of patients in
Externí odkaz:
https://doaj.org/article/3f86af985baa4e6283f302dee1bbb3e7
Autor:
Roman K. Thomas, Jürgen Wolf, Lukas C. Heukamp, Reinhard Büttner, Francois Ringeisen, H. Christian Reinhardt, Roland T. Ullrich, Thomas Zander, Daniel Rauh, Steffi Silling, Julie George, Srivari Chandrasekhar, Nagaraju Karre, Prathama S. Mainkar, Alexandra Florin, Martin Peifer, André Richters, Frauke Leenders, Danila Seidel, Marc Bos, Matthias Scheffler, Masyar Gardizi, Dennis Plenker, Joachim Diebold, Oliver Gautschi, Johannes M. Heuckmann, Lynnette Fernandez-Cuesta, Kerstin Albus, Lucia Nogova, Xin Lu, Jakob Schöttle, Felix Dietlein, Florian Malchers
PDF file 136K,Methods: Additional information on experimental techniques and data analysis. Legends: describing supplementary figures S1-S14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad5cc41fa20095c9341ef451390a6d5f
https://doi.org/10.1158/2159-8290.22529610
https://doi.org/10.1158/2159-8290.22529610
Autor:
Roman K. Thomas, Jürgen Wolf, Lukas C. Heukamp, Reinhard Büttner, Francois Ringeisen, H. Christian Reinhardt, Roland T. Ullrich, Thomas Zander, Daniel Rauh, Steffi Silling, Julie George, Srivari Chandrasekhar, Nagaraju Karre, Prathama S. Mainkar, Alexandra Florin, Martin Peifer, André Richters, Frauke Leenders, Danila Seidel, Marc Bos, Matthias Scheffler, Masyar Gardizi, Dennis Plenker, Joachim Diebold, Oliver Gautschi, Johannes M. Heuckmann, Lynnette Fernandez-Cuesta, Kerstin Albus, Lucia Nogova, Xin Lu, Jakob Schöttle, Felix Dietlein, Florian Malchers
PDF file 34156K, Table of genes from 16 recurrent amplified genomic regions (Figure S1), amplicon focality on TCGA copy number aberrations (Figure S2), hierarchical clustering of CLCGP copy number data (Figure S3), centrality frequencies of common ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaa55b970728bba259689298cf12daa2
https://doi.org/10.1158/2159-8290.22529613
https://doi.org/10.1158/2159-8290.22529613
Autor:
Xavier Pivot, A. Bailey, Francois Ringeisen, Gregory L Price, G. Cuyun Carter, H. Ostojic, Katie Lewis, A. Davie, Alex Rider
Publikováno v:
ESMO Open
Background Patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) and disease-related poor prognostic factors are not well characterized. We aimed to describe patient de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c54c6efe5ac6ba2f2acc2a12e24d22b5
https://pubmed.ncbi.nlm.nih.gov/34371379
https://pubmed.ncbi.nlm.nih.gov/34371379
Autor:
Alejo Cassinello, Luis Manso, Antonio Llombart, Miguel Martin, Manuel Atienza, Eva Ciruelos, Francois Ringeisen, José A. García-Sáenz
Publikováno v:
Future oncology (London, England). 16(33)
The addition of CDK4 and 6 inhibitors (abemaciclib, palbociclib or ribociclib) to endocrine therapy, as first-line treatment or following progression after initial endocrine therapy, significantly increased progression-free survival, objective respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8e78508f42d5f9f3c7801c0936840c9
https://pubmed.ncbi.nlm.nih.gov/32781837
https://pubmed.ncbi.nlm.nih.gov/32781837
Autor:
Davie, Alison, Gebra Cuyun Carter, Rider, Alex, Pike, James, Lewis, Katie, Bailey, Abigail, Price, Gregory L., Francois Ringeisen, Pivot, Xavier
Additional file 5: Table S5. Country-specific patient-reported EQ-5D scores.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57f9e142e64ef92a304668cbacb8ac70
Autor:
Davie, Alison, Gebra Cuyun Carter, Rider, Alex, Pike, James, Lewis, Katie, Bailey, Abigail, Price, Gregory L., Francois Ringeisen, Pivot, Xavier
Additional file 1: Table S1. Sample sizes for analysis cohort (women with HR+/HER2− advanced breast cancer currently receiving initial ET-based for advanced disease).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5518e955a80713165f2a349461851de7
Autor:
Davie, Alison, Gebra Cuyun Carter, Rider, Alex, Pike, James, Lewis, Katie, Bailey, Abigail, Price, Gregory L., Francois Ringeisen, Pivot, Xavier
Additional file 3: Table S3. Key characteristics of women with HR+/HER2− advanced breast cancer currently receiving initial endocrine-based therapy for advanced disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af76591a8571904e248c37801bdc15b6
Autor:
Davie, Alison, Gebra Cuyun Carter, Rider, Alex, Pike, James, Lewis, Katie, Bailey, Abigail, Price, Gregory L., Francois Ringeisen, Pivot, Xavier
Additional file 6: Table S6A. Factors associated with HRQoL (EORTC QLQ-C30 global health/QoL scale score) from multiple linear regression analysis for patients with HR+/HER2− advanced breast cancer currently receiving initial endocrine-based therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31603cda5ddc617ac4ec53e8505e6a33